Investor Presentaiton

FY23 Guidance 2023 Outlook as of July 27, 2023 Objectives & Considerations • • Global rollout of G7 Expansion of Dexcom ONE into new geographies • Building momentum in type 2 basal Strong year-over-year operating expense leverage Revenue of $3.500 - 3.550 billion (~20-22% Growth) Gross Margin of ~63% Operating Margin of ~17% Adjusted EBITDA Margin of ~26.5% We expect global momentum to build in 2023 and create a foundation of growth for years to come Dexcom 4

View entire presentation